Year: 2026

Bombardier Announces Extension of Consent Solicitation with Respect to its 7.35% Debentures due 2026

Written by Customer Service on March 30, 2026. Posted in Public Companies.

MONTRÉAL, March 30, 2026 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier”) today announced that it has extended the expiration date of its previously announced consent solicitation (the “Canadian Consent Solicitation”) in respect of its 7.35% Debentures due 2026 (the “Canadian Notes”). The Consent Deadline (as defined in the Consent Solicitation Statement referred to below) for the Canadian Notes has been extended to 5:00 p.m., Eastern time, on April 10, 2026 (the “Extended Consent Deadline”). As previously announced and described in Bombardier’s Consent Solicitation Statement dated March 16, 2026 (as it may be amended or supplemented, the “Consent Solicitation Statement”), if the requisite consents from holders of Canadian Notes are received on or prior to the Extended Consent Deadline and the supplemental indenture implementing...

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

Written by Customer Service on March 30, 2026. Posted in Public Companies.

– Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically meaningful improvements in ambulation and pulmonary function – Based on ongoing discussions with the FDA, BridgeBio anticipates approval with a U.S. launch anticipated in late 2026/early 2027 – If approved, BBP-418 has the potential to become the first and only therapy for individuals living with LGMD2I/R9 and may represent the first approved treatment for any form of LGMD PALO ALTO, Calif., March 30, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced the submission of its New...

Bitfarms to Participate in Jefferies Fireside Chat

Written by Customer Service on March 30, 2026. Posted in Public Companies.

TORONTO, Ontario and NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) — Bitfarms Ltd. (NASDAQ/TSX: BITF), a North American digital infrastructure and energy company, will participate in a fireside chat at the Jefferies Virtual Power x Data Center Conference. Jefferies Virtual Fireside ChatDate: Tuesday, March 31, 2026Time: 10:15 AM EasternPresenters: CEO, Ben Gagnon and CFO Jonathan Mir Webcast Link About Bitfarms Ltd.Bitfarms is a North American digital infrastructure and energy company that develops and owns data centers and energy infrastructure for high-performance computing workloads, including artificial intelligence. Bitfarms’ 2.1 GW North American energy portfolio is comprised of energized, under development, and pipeline MW, located in established data center clusters, with robust access to power and fiber infrastructure. Bitfarms...

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

Written by Customer Service on March 30, 2026. Posted in Public Companies.

Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab in pyoderma gangrenosum (PG) were featured in an oral presentation during the Late-Breaking Research abstract session at the 2026 American Academy of Dermatology (AAD) Annual Meeting being held March 27-31, 2026, in Denver, CO. The data presented included encouraging signals of clinical activity across multiple measures, with higher rates of complete remission, target ulcer closure, and reductions in ulcer volume, as well as a positive safety profile. The presentation, entitled “Vilobelimab Treatment for Ulcerative Pyoderma Gangrenosum: Results from a Multicenter, Randomized, Placebo...

NEURONES: Declaration of transactions on treasury shares (March 23 to 27, 2026)

Written by Customer Service on March 30, 2026. Posted in Public Companies.

Nanterre, March 30, 2026 Declaration of transactions on treasury shares(period from 23 to 27 March 2026) As part of the share buyback program authorized by the General Meeting of June 5, 2025 and entrusted to CIC, NEURONES made the following purchases between March 23 and 27, 2026 (ISIN code FR0004050250):Day Total daily volume(in number of shares) Weighted average price(unit daily)03/23/2026 46,392 34.13 €03/24/2026 42,993 33.47 €03/25/2026 11,665 34.58 €03/26/2026 7,166 34.26 €03/27/2026 6,805 34.43 €Total 115,021 As of March 27, 2026, excluding the liquidity contract, NEURONES now holds 230,861 of the 24,328,716 shares comprising the company’s capital (i.e., 0.95%). All press releases relating to the share buyback program are published in the “Regulated Information” section (under “Weekly...

Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

Written by Customer Service on March 30, 2026. Posted in Public Companies.

Alignment reached on key elements of ATH434 Phase 3 development program MELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA). The Type C Meeting is part of a multidisciplinary strategy to seek alignment with the FDA on readiness to initiate a Phase 3 pivotal trial in MSA. Alterity received written feedback supporting its plans related to the clinical pharmacology and non-clinical development elements...

Vireo Growth Inc. Announces Update on Non-Binding Memorandum of Understanding to Acquire The Hawthorne Gardening Company from ScottsMiracle-Gro

Written by Customer Service on March 30, 2026. Posted in Mergers And Acquisitions.

Planned share-based transaction is expected to be completed during the second quarter of 2026 Vireo plans to appoint ScottsMiracle-Gro EVP Chris Hagedorn to its Board of Directors MINNEAPOLIS, March 30, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) (“Vireo” or the “Company”) today announced an update on its previously announced nonbinding Memorandum of Understanding (“MOU”) with The Scotts Miracle-Gro Company (“ScottsMiracle-Gro”) to acquire The Hawthorne Gardening Company LLC (including certain of its subsidiaries, “Hawthorne”), an operating subsidiary of ScottsMiracle-Gro and leading provider of nutrients, lighting and other materials used for indoor and hydroponic gardening in North America (the “Hawthorne Transaction”). The Hawthorne Transaction could close any time following five (5) business...

Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Written by Customer Service on March 30, 2026. Posted in Earnings Releases And Operating Results.

Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability Completed with New Formulation with Potential Across Non-ocular Solid Tumor Indications, Beginning with Urologic Oncology BOSTON, March 30, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights. “2025 has been a year of focused execution across our clinical portfolio, with significant progress in trial enrollment, highlighted by the acceleration of our global Phase...

USA Rare Earth Reports Fourth Quarter and Full-Year 2025 Financial Results

Written by Customer Service on March 30, 2026. Posted in Earnings Releases And Operating Results.

STILLWATER, Okla., March 30, 2026 (GLOBE NEWSWIRE) — USA Rare Earth, Inc. (Nasdaq: USAR) (the Company), an emerging global leader in rare earths, today announced its financial and operational results for the fourth quarter and year ended December 31, 2025. Executive Commentary “2025 was the year that USA Rare Earth set the foundation to execute our integrated rare earth growth strategy,” said Barbara Humpton, CEO of USA Rare Earth. “We acquired the unique and internationally well-known metal and alloy making asset Less Common Metals, and we accelerated our progress toward mining development and magnet manufacturing. We are now rapidly developing a leading, globally integrated rare earth value chain that spans mining, processing, metal-making and magnet manufacturing, for the benefit of the U.S. and our allies. We are also attracting...

PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement

Written by Customer Service on March 30, 2026. Posted in Earnings Releases And Operating Results.

Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs Conference Call and Webcast Today at 8:00 am Eastern Time PRINCETON, N.J., March 30, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter and year ended December 31, 2025. “The fourth quarter capped a year of important progress for PDS Biotech, marked by meaningful advances across our clinical programs, financial discipline, and intellectual property portfolio,” said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. “Building on the...

Year: 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals